In this article, we will look at the 12 Most Profitable Blue Chip Stocks to Invest In Now. On March 12, Stephen Parker, JPMorgan Private Bank co-head of global investment strategy, appeared on CNBC’s ...

In this article, we will discuss the Goldman Sachs Healthcare Stocks: Top 10 Stock Picks. The healthcare sector, long seen as ...

International stocks spent the better part of the last decade underperforming their U.S. counterparts, but that changed last ...

British drugmaker AstraZeneca Plc has emerged as the leading contender to acquire French biotech Abivax SA, following the company's dramatic valuation surge after strong clinical progress tied to its ...

Astrazeneca (AZN) concluded the recent trading session at $189.9, signifying a -1.35% move from its prior day's close.

Retirees hunting for income beyond U.S. borders have increasingly turned to iShares MSCI United Kingdom ETF (NYSEARCA:EWU), which packages the dividend-rich London Stock Exchange into a single, ...

Biotechnology company Abivax on Thursday dismissed a report by ​French media publication La Lettre saying it ‌had granted ...

French biotech Abivax has been the subject of intense takeover speculation for months. But a spokesperson denied a report by La Lettre that AstraZeneca was ...

During this latest round of earnings calls, marketing didn’t factor heavily in these discussions. Lilly did address sharply rising commercial costs which go in tandem with its massive revenue growth, ...

The Harbor International Compounders Fund returned 3.19% in Q4 2025, trailing its benchmark. Read the full analysis for more ...

A decade ago, more than 63% of the pharmaceutical giant's revenue was tied up in one drug -- Humira. Granted, it was the top-selling drug in the world at the time. But despite the 130 patents it ...

AstraZeneca PLC closed 0.08% below its 52-week high of £155.54, which the company achieved on February 24th.